Mental Health DailyResearch. Evidence. Perspective.Published research on Withdrawal.
Fetzima (Levomilnacipran), is a serotonin-norepinephrine reuptake inhibitor (SNRI) that was approved by the United States FDA in 2013 for the treatment of major depressive disorder. It was e…
Read articleOmeprazole, manufactured the trade names Prilosec and Losec, is a proton-pump inhibitor prescribed for the management of medical conditions such as: gastroesophageal reflux disease (GERD); p…
Read articleRexulti (Brexpiprazole) is an atypical antipsychotic that is most commonly utilized as a pharmacologic intervention for the management of schizophrenia, and in some cases, as an add-on (adju…
Read articleVraylar (Cariprazine) is an atypical antipsychotic that is most frequently prescribed as a pharmacological intervention for schizophrenia and bipolar disorder. The medication functions predo…
Read articleTianeptine, also referred to under the brand names “Stablon” and “Coaxil,” is an antidepressant originally discovered and patented in the 1960s by the French Society of Medical Research. The…
Read articleBunavail is a bucally-formatted medication comprised of buprenorphine and naloxone that was approved by the FDA in 2017 for the treatment of opioid dependence. The buprenorphine component of…
Read articleIbogaine is a psychoactive indole alkaloid derived from plants of the Apocynaceae family, including: Tabernanthe iboga, Voacanga africana and Tabernaemontana undulata. When ingested by human…
Read article